PeptideDB

KDM5-IN-48 1628210-26-3

KDM5-IN-48 1628210-26-3

CAS No.: 1628210-26-3

KDM5-IN-48 is a novel, potent, selective and orally bioavailable KDM5 inhibitor (IC50 o=15.1 nM). KDM5-IN-48 has improve
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

KDM5-IN-48 is a novel, potent, selective and orally bioavailable KDM5 inhibitor (IC50 o=15.1 nM). KDM5-IN-48 has improved cell potency (PC9 H3K4Me3 EC50=0.34μM). Furthermore, KDM5-IN-48 maintained suitable physiochemical properties and displayed an excellent pharmacokinetic (PK) profile in mice. When dosed orally in mice at 50mg/kg twice a day (BID), KDM5-IN-48 showed an unbound maximal plasma concentration (Cmax) >15-fold over its cell EC50, thereby providing a robust chemical probe for studying KDM5 biological functions in vivo.



Physicochemical Properties


Molecular Formula C17H20N6O
Molecular Weight 324.3803
Exact Mass 324.169
CAS # 1628210-26-3
PubChem CID 118908379
Appearance White to off-white solid powder
Density 1.3±0.1 g/cm3
Boiling Point 527.0±60.0 °C at 760 mmHg
Flash Point 272.5±32.9 °C
Vapour Pressure 0.0±1.4 mmHg at 25°C
Index of Refraction 1.659
LogP 1.64
Hydrogen Bond Donor Count 1
Hydrogen Bond Acceptor Count 5
Rotatable Bond Count 3
Heavy Atom Count 24
Complexity 715
Defined Atom Stereocenter Count 0
InChi Key KRXWJZIHQRIGSJ-UHFFFAOYSA-N
InChi Code

InChI=1S/C17H20N6O/c1-10(2)13-14(12-8-19-22(9-12)17(3,4)5)21-15-11(6-18)7-20-23(15)16(13)24/h7-10,21H,1-5H3
Chemical Name

5-[1-(1,1-Dimethylethyl)-1H-pyrazol-4-yl]-4,7-dihydro-6-(1-methylethyl)-7-oxo-pyrazolo[1,5-a]pyrimidine-3-carbonitrile
Synonyms

KDM5-IN-48 KDM5 IN 48 KDM5IN48 KDM5 inhibitor-48 KDM5 inhibitor 48
HS Tariff Code 2934.99.9001
Storage

Powder-20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

Shipping Condition Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity


ln Vitro KDM5B and KDM5C isoforms were shown to be potently inhibited by KDM5-IN-1 (IC50 values of 4.7 and 65.5 nM, respectively). Its impact on other KDM enzymes (1A, 2B, 3B, 4C, 5A, 6A, and 7B) is noticeably weaker. With an IC50 of 1.9 μM, it exhibits the largest inhibitory effect on KDM4C. Even so, KDM5-IN-1's selectivity for KDM4C is still more than 100 times greater than KDM5A's [1].
ln Vivo KDM5-IN-1 demonstrated an unbound maximum plasma concentration Cmax >15 times its cellular EC50 when given orally to mice at a dose of 50 mg/kg twice daily, offering a strong platform for researching the in vivo biological functions of KDM5. chemical investigation tools[1].
References

[1]. Lead optimization of a pyrazolo[1,5-a]pyrimidin-7(4H)-one scaffold to identify potent, selective and orally bioavailable KDM5 inhibitors suitable for in vivo biological studies. Bioorg Med Chem Lett. 2016 Aug 15;26(16):4036-41.


Solubility Data


Solubility (In Vitro) DMSO : ≥ 30 mg/mL (~92.48 mM)
Solubility (In Vivo) Solubility in Formulation 1: ≥ 2.5 mg/mL (7.71 mM) (saturation unknown) in 5% DMSO + 40% PEG300 + 5% Tween80 + 50% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: ≥ 2.08 mg/mL (6.41 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 3: ≥ 2.08 mg/mL (6.41 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 3.0828 mL 15.4140 mL 30.8280 mL
5 mM 0.6166 mL 3.0828 mL 6.1656 mL
10 mM 0.3083 mL 1.5414 mL 3.0828 mL
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.